The Roles of Blood Proteins in Haematological Malignancies

Recent evidence has demonstrated that JAK2 V617F needs to directly associate with a functional homodimeric type I cytokine in order to drive myeloproliferative neoplasms (MPNs). By identifying new pathways that control the function of mutant JAK2, in addition to investigating how thrombopoietin (TPO) signalling regulates MPN progression we aim to design new drugs for future MPN therapies.